Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ.

Dabbs D, Mittal K, Heineman S, Whitworth P, Shah C, Savala J, Shivers SC, Bremer T

Open source

DOI
10.3389/fonc.2023.1069059
Published
2023
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2023.1069059,
  title = {Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ.},
  author = {Dabbs D and Mittal K and Heineman S and Whitworth P and Shah C and Savala J and Shivers SC and Bremer T},
  year = {2023},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2023.1069059},
  url = {https://doi.org/10.3389/fonc.2023.1069059}
}

RIS

TY  - JOUR
TI  - Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ.
AU  - Dabbs D
AU  - Mittal K
AU  - Heineman S
AU  - Whitworth P
AU  - Shah C
AU  - Savala J
AU  - Shivers SC
AU  - Bremer T
PY  - 2023
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2023.1069059
UR  - https://doi.org/10.3389/fonc.2023.1069059
ER  - 

APA

D, D., K, M., S, H., P, W., C, S., J, S., SC, S., & T, B. (2023). Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ.. Frontiers in oncology. https://doi.org/10.3389/fonc.2023.1069059

Source records